A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation-Reference-Cited by-同舟云学术

A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation

Published:2015-02-23 Issue:6 Volume:94 Page:526-531
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Heimann Sebastian M.¹,Vehreschild Maria J.G.T.¹²,Cornely Oliver A.¹³⁴⁵,Franke Bernd¹,von Bergwelt-Baildon Michael¹⁵,Wisplinghoff Hilmar⁶,Kron Florian¹,Scheid Christoph¹,Vehreschild Jörg J.¹²

Affiliation:

1. 1st Department of Internal Medicine; University Hospital of Cologne; Cologne Germany

2. German Centre for Infection Research, Partner Site Bonn-Cologne; Cologne Germany

3. Clinical Trials Centre Cologne; ZKS Köln (BMBF01KN1106); University Hospital of Cologne; Cologne Germany

4. Cluster of Excellence - Cellular Stress Responses in Aging-Associated Diseases; CECAD; University of Cologne; Cologne Germany

5. Center for Integrated Oncology Köln Bonn; CIO Köln Bonn; University Hospital of Cologne; Cologne Germany

6. Institute for Medical Microbiology, Immunology and Hygiene; University Hospital of Cologne; Cologne Germany

Funder

Astellas Pharma Germany

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12466/fullpdf

Reference27 articles.

1. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database;Kontoyiannis;Clin Infect Dis,2010

2. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation;Herbrecht;J Antimicrob Chemother,2012

3. Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success;Kontoyiannis;Bone Marrow Transplant,2011

4. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry;Neofytos;Clin Infect Dis,2009

5. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation;Goodman;N Engl J Med,1992

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Invasive fungal infections in hematologic malignancies: Incidence, management, and antifungal therapy;Journal of Research in Medical Sciences;2023-09

2. T-LYMPHOCYTES EXPRESSION OF TOLL-LIKE RECEPTORS 2 AND 4 IN ACUTE MYELOID LEUKEMIA PATIENTS WITH INVASIVE FUNGAL INFECTIONS;Mediterranean Journal of Hematology and Infectious Diseases;2022-02-27

3. The impact of donor type on resource utilisation and costs in allogeneic haematopoietic stem cell transplantation in the Netherlands;European Journal of Haematology;2022-01-13

4. Clinical and pharmacoeconomic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: A six‐year cohort analysis;Mycoses;2021-01-06

5. Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: A retrospective analysis;European Journal of Haematology;2020-01-20